Why Amylyx is pulling ALS drug Relyvrio from US market after study
Release time：2024-04-30 08:40:04 Source：Worldly Wisdom news portal
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
- Previous：The North London neighbourhood plagued by anti
- Next：A bomb attack in northern Kenya kills 5 people near the border with Somalia
Related articles
- Music and martial arts witness China
- Baltimore bridge collapses after being struck by ship, six presumed dead
- Baltimore bridge collapses after being struck by ship, six presumed dead
- Finnish police say bullying was motive for school shooting
- Ecuador announces complaint against Mexico at top UN court in diplomatic spat
- More productive land being used for urban development, study finds
- Yemen's Houthis say they targeted Western ships
- 'Devastated': Widow pleads for late husband’s dream to be realised
- Music and martial arts witness China
- UN suspends aid movements at night in Gaza
- Chinese enterprises keen to expand int'l market: Trade council
- Tech industry plans for lower
- China news: Mystery as Xi Jinping unexpectedly skips key speech
- Death toll rises in Taiwan's strongest earthquake in 25 years
- Explosion kills 3 including 2 children in Myanmar's Yangon
- US restricts trade with companies tied to drones used by Russia, Houthis
- Finnish police say bullying was motive for school shooting
- HK gov't declines to say how much funding it gave for 'Chubby Hearts'
- Ecuador announces complaint against Mexico at top UN court in diplomatic spat
- Indigenous deaths in custody haunt Australia
Random recommendation
- Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Worldly Wisdom news portal sitemap